Vivos Therapeutics (VVOS)

Vivos Therapeutics Stock Analysis & Ratings

VVOS Stock Chart & Stats

Day’s Range$1.27 - $1.48
52-Week Range$1.18 - $7.09
Previous Close$1.35
Average Volume (3M)1.55M
Market Cap$32.02M
P/E Ratio-1.4
Next EarningsAug 11, 2022
EPS ForecastN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
1Y Price TargetN/A
Smart Score3
EPS (TTM)-0.96

Vivos Therapeutics News

Currently, no data available
Please return soon. This page is being updated.




P/E Ratio Range

The price to earnings ratio. This is used by investors to assess a stock’s market price relative to its earnings.


Risk Analysis

Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy

Product Monthly Users

Sorry, No Data Available
There is no website visitor data available for this stock.



What was Vivos Therapeutics’s price range in the past 12 months?
Vivos Therapeutics lowest stock price was $1.18 and its highest was $7.09 in the past 12 months.
    What is Vivos Therapeutics’s market cap?
    Vivos Therapeutics’s market cap is $32.02M.
      What is Vivos Therapeutics’s price target?
      Currently, no data Available
      What do analysts say about Vivos Therapeutics?
      Vivos Therapeutics’s analyst rating consensus is a ‘Moderate Buy. This is based on the ratings of 1 Wall Streets Analysts.
        When is Vivos Therapeutics’s upcoming earnings report date?
        Vivos Therapeutics’s upcoming earnings report date is Aug 11, 2022 which is in 85 days.
          How were Vivos Therapeutics’s earnings last quarter?
          Currently, no data Available
          Is Vivos Therapeutics overvalued?
          According to Wall Street analysts Vivos Therapeutics’s price is currently Overvalued.
            Does Vivos Therapeutics pay dividends?
            Vivos Therapeutics does not currently pay dividends.
            What is Vivos Therapeutics’s EPS estimate?
            Vivos Therapeutics’s EPS estimate for its next earnings report is not yet available.
            How many shares outstanding does Vivos Therapeutics have?
            Vivos Therapeutics has 23,010,000 shares outstanding.
              What happened to Vivos Therapeutics’s price movement after its last earnings report?
              Currently, no data Available
              Which hedge fund is a major shareholder of Vivos Therapeutics?
              Among the largest hedge funds holding Vivos Therapeutics’s share is Royce & Associates LLC. It holds Vivos Therapeutics’s shares valued at N/A.


                Vivos Therapeutics Stock Analysis

                Smart Score
                Price Target
                No data currently available
                The Vivos Therapeutics stock analysis is based on the TipRanks Smart Score which is derived from 8 unique data sets including Analyst recommendations, Crowd Wisdom, Hedge Fund Activity, Media Sentiment and multiple Technical stock factors. The Smart Score is a quantitative, data-driven rating system and does not include human intervention.
                Learn more about TipRanks Smart Score

                Company Description

                Vivos Therapeutics

                Vivos Therapeutics Inc is a medical technology company. It is focused on the development and commercialization of a technology offering non-surgical, non-invasive, non-pharmaceutical, and low-cost solution for patients with sleep-disordered breathing (SDB), including mild-to-moderate obstructive sleep apnea (OSA). The company provides treatment of sleep-disordered breathing including mild-to-moderate obstructive sleep apnea resulting from underdeveloped upper and lower jaws.

                Similar Stocks
                No data currently available

                Popular Stocks

                What's Included in PREMIUM?
                Make informed decisions based on Top Analysts' activity
                Know what industry insiders are buying
                Get actionable alerts from top Wall Street Analysts
                Find out before anyone else which stock is going to shoot up
                Get powerful stock screeners & detailed portfolio analysis